Published in Mol Ther on May 17, 2011
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators. Front Immunol (2015) 1.01
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood (2013) 0.94
Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83
The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion. J Immunol (2014) 0.80
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78
T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Commun Signal (2017) 0.78
Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8⁺ T cell responses and protective immunity. PLoS One (2013) 0.77
BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine. Oncotarget (2015) 0.76
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2008) 10.26
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med (2003) 7.86
Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 5.33
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell (2001) 4.44
Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A (1991) 3.34
Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med (1999) 3.29
Adenoviruses as vaccine vectors. Mol Ther (2004) 3.09
CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol (2008) 2.99
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther (2001) 2.83
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood (2005) 2.60
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res (2007) 2.38
Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother (2009) 2.10
Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). J Virol (2002) 2.03
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci (2009) 1.96
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood (2009) 1.80
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res (2007) 1.44
Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology (2000) 1.44
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer (2006) 1.35
Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex. J Biol Chem (2005) 1.35
Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol (2008) 1.15
Targeting inhibitory pathways in cancer immunotherapy. Curr Opin Immunol (2010) 1.10
GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol (2006) 1.08
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog (2009) 1.08
Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med (2008) 1.07
Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun (2007) 1.06
Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine (2008) 1.01
Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 1.01
Augmentation of primary influenza A virus-specific CD8+ T cell responses in aged mice through blockade of an immunoinhibitory pathway. J Immunol (2010) 0.99
Tissue-specific expression and methylation of a thyroglobulin-chloramphenicol acetyltransferase fusion gene in transgenic mice. Proc Natl Acad Sci U S A (1990) 0.95
Increased responsiveness to toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis. Mediators Inflamm (2008) 0.95
Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect (2005) 0.87
Differentiated carcinomas develop as a consequence of the thyroid specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene. Oncogene (1995) 0.86
Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol (2010) 0.83
Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell (2009) 14.40
Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science (2007) 7.64
Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature (2003) 7.56
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 5.14
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity (2006) 3.92
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell (2010) 3.52
Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity (2005) 3.39
Adaptive immune cells temper initial innate responses. Nat Med (2007) 3.37
The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity (2011) 3.32
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 3.26
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med (2005) 3.01
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Recognition of host immune activation by Pseudomonas aeruginosa. Science (2005) 2.84
Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. Microbiology (2002) 2.71
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe (2011) 2.46
Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol (2006) 2.44
Random migration precedes stable target cell interactions of tumor-infiltrating T cells. J Exp Med (2006) 2.43
CD95 promotes tumour growth. Nature (2010) 2.42
Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells. Nature (2012) 2.38
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med (2002) 2.23
Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med (2010) 2.22
Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 2.17
Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med (2009) 2.12
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med (2013) 2.07
Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science (2007) 2.06
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05
Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity (2013) 2.01
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest (2006) 2.00
Lymphotoxin regulates commensal responses to enable diet-induced obesity. Nat Immunol (2012) 1.99
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med (2010) 1.97
Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine depots. Nat Immunol (2011) 1.93
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol (2013) 1.91
Migratory dermal dendritic cells act as rapid sensors of protozoan parasites. PLoS Pathog (2008) 1.90
Cutaneous immunosurveillance by self-renewing dermal gammadelta T cells. J Exp Med (2011) 1.85
Behavior of parasite-specific effector CD8+ T cells in the brain and visualization of a kinesis-associated system of reticular fibers. Immunity (2009) 1.84
Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology (2008) 1.84
The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest (2005) 1.82
Lymphotoxin pathway directs thymic Aire expression. Nat Immunol (2003) 1.79
Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol (2003) 1.75
A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res (2009) 1.72
CD44 mediates successful interstitial navigation by killer T cells and enables efficient antitumor immunity. Immunity (2008) 1.72
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. Immunity (2012) 1.70
LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology (2007) 1.70
Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol (2007) 1.69
Enteric salmonella infection inhibits Paneth cell antimicrobial peptide expression. Infect Immun (2003) 1.69
Evaluation of rapid cooling and tricaine methanesulfonate (MS222) as methods of euthanasia in zebrafish (Danio rerio). J Am Assoc Lab Anim Sci (2009) 1.68
Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med (2003) 1.68
Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol (2005) 1.65
The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A (2004) 1.63
B and T lymphocyte attenuator regulates CD8+ T cell-intrinsic homeostasis and memory cell generation. Nat Immunol (2007) 1.61
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol (2007) 1.60
Type I interferon response and innate immune sensing of cancer. Trends Immunol (2012) 1.59
Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J Clin Invest (2006) 1.57
The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol (2006) 1.56
Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest (2006) 1.56
Phenotype and functions of conventional dendritic cells are not compromised in aged mice. Immunol Cell Biol (2012) 1.53
Visualizing the neutrophil response to sterile tissue injury in mouse dermis reveals a three-phase cascade of events. J Invest Dermatol (2011) 1.51
Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature (2003) 1.51
Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity (2010) 1.50
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med (2003) 1.49
Langerhans cells are precommitted to immune tolerance induction. Proc Natl Acad Sci U S A (2011) 1.47
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol (2002) 1.45
Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol (2013) 1.44
OX40 signaling favors the induction of T(H)9 cells and airway inflammation. Nat Immunol (2012) 1.43
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood (2005) 1.43
Foxp1 is an essential transcriptional regulator for the generation of quiescent naive T cells during thymocyte development. Blood (2009) 1.42
Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity (2006) 1.40
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res (2008) 1.39
High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res (2009) 1.39
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol (2007) 1.38
Dynamic Imaging of CD8(+) T cells and dendritic cells during infection with Toxoplasma gondii. PLoS Pathog (2009) 1.37
Bacterial colonization of nasal mucosa induces expression of siderocalin, an iron-sequestering component of innate immunity. Cell Microbiol (2005) 1.36
Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production. Nat Immunol (2002) 1.36
Intravital multiphoton imaging of immune responses in the mouse ear skin. Nat Protoc (2012) 1.35
Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol (2005) 1.33
Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood (2007) 1.33
Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc Natl Acad Sci U S A (2008) 1.33
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Tumor necrosis factor family members and inflammatory bowel disease. Immunol Rev (2005) 1.29
NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest (2006) 1.29
Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol (2005) 1.29
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Dysregulated LIGHT expression on T cells mediates intestinal inflammation and contributes to IgA nephropathy. J Clin Invest (2004) 1.28